DeepMed Research

Methylnaltrexone

Generic Name: Methylnaltrexone

Brand Names: Relistor

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆NO_₄

CAS Number: 916055-93-1

Unique Ingredient Identifier: 0RK7M7IABE

Background: Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008.

Indication: Treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy.

Associated Conditions: Opioid Induced Constipation (OIC)

Clinical Trials

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Phase 4

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Methylnaltrexone

First Posted Date: 2023-12-08

Last Posted Date: 2025-02-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT06162377

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

RELISTOR's Effects on Opioid-Induced Constipation

Withdrawn

Conditions: OIC

Interventions: Drug: Docusate Calcium
Drug: Relistor Injectable Product
Drug: Bisacodyl
Drug: Milk of magnesia
Drug: Magnesium citrate
Drug: Senna
Drug: Enema

First Posted Date: 2021-06-18

Last Posted Date: 2022-05-03

Lead Sponsor: Methodist Health System

Registration Number: NCT04930237

Locations: 🇺🇸
Methodist Moody Brain and Spine Institute, Methodist Dallas Medical Center, Dallas, Texas, United States

Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

Not Applicable

Recruiting

Conditions: Chronic Widespread Pain

Interventions: Drug: Relistor Injectable Product

First Posted Date: 2021-03-09

Last Posted Date: 2025-02-19

Lead Sponsor: Florida International University

Target Recruit Count: 200

Registration Number: NCT04787848

Locations: 🇺🇸
Ambulatory Care Center, Florida International University, Miami, Florida, United States

Effects of Peripherally Acting µ-opioid Receptor Antagonists on Acute Pancreatitis

Phase 2

Completed

Conditions: Acute Pancreatitis

Interventions: Drug: Placebo treatment
Drug: Methylnaltrexone treatment

First Posted Date: 2021-02-08

Last Posted Date: 2023-04-21

Lead Sponsor: Asbjørn Mohr Drewes

Target Recruit Count: 105

Registration Number: NCT04743570

Locations: 🇩🇰
Mech-Sense, Department of Medical Gastroenterology, Aalborg University Hospital, Aalborg, Jutland, Denmark
🇩🇰
Digestive Disease Center K, Bispebjerg University Hospital, Bispebjerg, Denmark
🇩🇰
Gastrounit, Hvidovre University Hospital, Hvidovre, Denmark

and more 1 locations

An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Phase 3

Withdrawn

Conditions: Pancreatic Cancer

Interventions: Drug: Methylnaltrexone bromide (MNTX)

First Posted Date: 2019-11-05

Last Posted Date: 2021-05-07

Lead Sponsor: Bausch Health Americas, Inc.

Registration Number: NCT04151719

A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Phase 2

Withdrawn

Conditions: Pancreatic Cancer

Interventions: Drug: Placebo
Drug: Methylnaltrexone bromide

First Posted Date: 2019-09-10

Last Posted Date: 2021-05-07

Lead Sponsor: Bausch Health Americas, Inc.

Registration Number: NCT04083651

Locations: 🇺🇸
Bausch Site 001, Omaha, Nebraska, United States

Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention

Phase 2

Completed

Conditions: Postoperative Ileus

Interventions: Other: Placebo
Drug: Methylnaltrexone

First Posted Date: 2019-02-25

Last Posted Date: 2021-10-27

Lead Sponsor: Ohio State University

Target Recruit Count: 82

Registration Number: NCT03852524

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

Phase 4

Completed

Conditions: Constipation Drug Induced

Interventions: Drug: Methylnaltrexone Bromide 150 mg Oral Tablet
Drug: Naloxegol 25 MG Oral Tablet
Drug: Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1

First Posted Date: 2018-05-14

Last Posted Date: 2023-04-11

Lead Sponsor: University of Missouri-Columbia

Target Recruit Count: 15

Registration Number: NCT03523520

Locations: 🇺🇸
Kara B. Goddard, Columbia, Missouri, United States

The Effect of Naloxone and Methylnaltrexone on Esophageal Sensitivity in Health

Not Applicable

Completed

Conditions: Endogenous and Esophageal Sensitivity

Interventions: Other: Placebo
Drug: Naloxone
Drug: Methylnaltrexone Bromide

First Posted Date: 2017-01-09

Last Posted Date: 2017-01-09

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 12

Registration Number: NCT03014843

Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

Phase 4

Terminated

Conditions: Constipation

Interventions: Drug: Placebo Oral Tablet
Drug: Naloxegol Oral Tablet
Drug: Docusate Sodium 100 Mg oral capsule [Colace]
Drug: Senna 217 Mg Oral Tablet
Drug: Polyethylene Glycols
Drug: Bisacodyl 10 mg Suppository
Drug: Magnesium Citrate Oral Liquid Product
Drug: Methylnaltrexone

First Posted Date: 2016-11-30

Last Posted Date: 2023-02-16

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 12

Registration Number: NCT02977286

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy